CLINICAL TRIALS OFFICE

CLINICAL TRIALS OFFICE

Established in 1997, our Clinical Trials Office incorporates experts conducting clinical trials at the Vall d’Hebron University Hospital’s (HUVH) Oncology Department. More specifically, our professionals including study coordinators, data managers, administrative staff and quality control, coordinate studies from Phase I to Phase III as well as various research projects. Divided into three groups, covering all tumor types and studies, our teams are managed by the Clinical Trials Office Director, Gemma Sala.

As we continue to render personalized medicine more precise by better targeting therapies to respond to the specificities of each individual patient, each individual tumor, the requirements and selection criteria for inclusion in certain studies are also becoming more complex. While we are dedicated to expanding our portfolio of trials in order to ultimately establish new treatment models with highly selective drugs, we must also continue to fine-tune patient selection criteria in order to best identify those patients who are most likely to benefit from novel therapies, including emerging immunotherapeutics, matched to each individual’s molecular ‘measurements’.

The Vall d’Hebron University Hospital’s Oncology Department has gained much prestige which has been acknowledged by pharmaceutical companies. It has consequently become a reference center selected by the industry to carry out complex clinical trials for which the number of participating centers is highly restricted. Selected sites are chosen based on their high standards of quality and capacity for carrying out state-of-the-art research. We have taken part in early phase trials of different drugs, ultimately enabling the pharmaceutical industry to market novel anti-cancer medicines. We participate in both clinical trials promoted by the pharmaceutical industry as well as those developed by our department in collaboration with other hospitals.

In 2017 we had 355 Phase I, Basket studies, Phases II & III trials with active recruitment during the same year (see Figure II), with patient enrolment totaling at 1096. 100 new trials were initiated, including 20 post-authorisation trials and rollover studies. In addition, we continue to follow up patients who were recruited prior to 2017 and are still enrolled and receiving study treatment (more than 1800 patients in total). (1999 – 2017) please click here.

For more information about Phase I, Basket studies, and early Phase II trials, please see  the Research Unit for Molecular Therapy of Cancer UITM – ”la Caixa”.


STRATEGIC GOALS

  • Contribute to the development of novel therapies against cancer.
  • Consolidation as an international reference for clinical trials in oncology.
  • Guide patients enrolled in trials to comply with the protocol requirements and help them with daily life throughout the duration of their participation.
  • Ensure that the protocol is appropriately conducted from initiation to the close of the respective clinical study.
  • Standardize clinical trial processes to ensure optimal quality and the compliance of Good Clinical Practice (GCP).

CURRENT OBJECTIVES

  • Contribute to the development of novel therapies against cancer.
  • Consolidation as an international reference for clinical trials in oncology.
  • Guide patients enrolled in trials to comply with the protocol requirements and help them with daily life throughout the duration of their participation.
  • Ensure that the protocol is appropriately conducted from initiation to the close of the respective clinical study.
  • Standardize clinical trial processes to ensure optimal quality and the compliance of Good Clinical Practice (GCP).

TEAM


Director

  • Marta Beltran

Head, Clinical Trials Office for Phase I Trials

  • Silivia Pérez

Study Coordinators

  • Eulalia Aliende
  • Ariadna Arasanz
  • Eva Belen Banus
  • Lluïsa Carbonell
  • Guillem Cunill
  • Raquel de La Torre
  • Nuria Farras
  • Maria Garcia
  • Maria Herranz
  • Andreu Martínez
  • Sonia Martinez
  • Anna Matres
  • Laura Maynés
  • Montserrat Moreno
  • Gemma Mur
  • Laura Oliva
  • Adelaida Piera
  • Mirieia Sanchis
  • Mireia Sole

Data Managers

  • Ariadna Arasanz
  • Ignacio Carcela
  • Marina Coll
  • Gloria Garcia
  • Jordina Llavall
  • Anna Martinez
  • Lidia Martinez De Arenzana
  • Carles Montoliu
  • Alejandro Pardines
  • Sergi Pérez
  • Xavier Pérez
  • Montserrat Pujadas
  • Rosa Maria Romero

Head, Clinical Trials Office for Phase II-III Clinical Trials (GI, Lung, Head & Neck, and Gyne)

  • Mara Beltran

Study Coordinators

  • Izar Achaerandio
  • Núria Bascuñana
  • Elena Fernandez
  • Laura Garcia
  • Raquel Garcia
  • Irene Garrido
  • Raquel Gutierrez
  • Cristina Pérez
  • Iratxe Puebla
  • Sergi Recasens
  • Laura Sanchez
  • Lorena Trejo
  • Angeles Valls
  • Román Vidal

Data Managers

  • Berta Feliu
  • Laura Garcia
  • Iris de la Fuente
  • Laia Gregori
  • Raquel Gutierrez
  • Eva Mª Lázaro
  • Eva Marín
  • Silvia Marín
  • Asal Rinaldi
  • Julia Serra
  • Eduard Solà

Head, Breast, GU, CNS, Sarcoma, Gynecological Clinical Trials

  • Meritxell Soler

Study Coordinators

  • Enric Álvarez
  • Nuria Collantes
  • Carlos Fernandez
  • Sergio Fernandez
  • Pol Gonzalez
  • Sara Gutierrez Fernandez
  • Montserrat Hernandez
  • Alba Meire
  • Thaïs Miquel
  • Olga Padrós
  • Mariona Pocarull
  • Angela Maria Quintana
  • Ester Serra

Data Managers

  • Cristina Aguilar
  • David Alvarez
  • Raquel Madrenas
  • Maria Isabel Martinez
  • Maria del Mar Suares
  • Carina Monclús 
  • Nuria Ortega

Head, Clinical Trials Hemtatology Group

Study Coordinators

  • Queralt Ferrer
  • Clara Lopez
  • Ana Mafalda Nunes
  • Judit Pinteño
  • Elena Sanchez
  • Julia Sedo
  • Laura Segura
  • Andrea Tricas

Data Managers

  • Josu Iraola
  • Alejandro Lahire
  • Magda Masana
  • Soraya Peralta
  • Aida Rebollo